Pharmaceuticals - Scandinavia Industry Guide
Published: January 2013 · Publisher: MarketLine
The Scandinavian pharmaceuticals market had a total market value of $10.0 2011 in 2011. Denmark was the fastest growing country with a CAGR of 4.7% over the 2007-11 period.
- Description
- Table of Contents
- Ask a Question
Introduction
The Scandinavian pharmaceuticals market had a total market value of $10.0 2011 in 2011. Denmark was the fastest growing country with a CAGR of 4.7% over the 2007-11 period.
Features and benefits
* Contains an executive summary, market values, and segmentation.
* Provides textual analysis of the industry's prospects, competitive landscape, and profiles of leading companies.
* Incorporates in-depth five forces competitive environment analysis and scorecards.
* Compares data from Denmark, Norway, and Sweden, alongside individual chapters on each country.
* Includes a five-year forecast of the industry.
Highlights
Within the pharmaceuticals industry, Sweden is the leading country among the Scandinavian countries, with market revenues of $4.7 2011 in 2011. This was followed by Denmark and Norway, with $3.1 and $2.1 2011, respectively.
Your key questions answered
* Spot future trends and developments.
* Inform your business decisions.
* Add weight to presentations and marketing materials.
* Save time carrying out entry-level research.
The Scandinavian pharmaceuticals market had a total market value of $10.0 2011 in 2011. Denmark was the fastest growing country with a CAGR of 4.7% over the 2007-11 period.
Features and benefits
* Contains an executive summary, market values, and segmentation.
* Provides textual analysis of the industry's prospects, competitive landscape, and profiles of leading companies.
* Incorporates in-depth five forces competitive environment analysis and scorecards.
* Compares data from Denmark, Norway, and Sweden, alongside individual chapters on each country.
* Includes a five-year forecast of the industry.
Highlights
Within the pharmaceuticals industry, Sweden is the leading country among the Scandinavian countries, with market revenues of $4.7 2011 in 2011. This was followed by Denmark and Norway, with $3.1 and $2.1 2011, respectively.
Your key questions answered
* Spot future trends and developments.
* Inform your business decisions.
* Add weight to presentations and marketing materials.
* Save time carrying out entry-level research.
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
TABLE OF CONTENTS
Introduction 7
What is this report about? 7
Who is the target reader? 7
How to use this report 7
Definitions 7
Scandinavia Pharmaceuticals 8
Industry Outlook 8
Pharmaceuticals in Denmark 11
Market Overview 11
Market Data 12
Market Segmentation 13
Market outlook 15
Five forces analysis 16
Macroeconomic indicators 24
Pharmaceuticals in Norway 26
Market Overview 26
Market Data 27
Market Segmentation 28
Market outlook 30
Five forces analysis 31
Macroeconomic indicators 39
Pharmaceuticals in Sweden 41
Market Overview 41
Market Data 42
Market Segmentation 43
Market outlook 45
Five forces analysis 46
Macroeconomic indicators 54
Company Profiles 56
Leading companies 56
Appendix 77
Methodology 77
LIST OF TABLES
Table 1: Scandinavia pharmaceuticals industry, revenue ($bn), 2007-16 8
Table 2: Scandinavia pharmaceuticals industry, revenue ($bn), 2007-11 9
Table 3: Scandinavia pharmaceuticals industry forecast, revenue ($bn), 2011-16 10
Table 4: Denmark pharmaceuticals market value: $ billion, 2007–11 12
Table 5: Denmark pharmaceuticals market geography segmentation: $ billion, 2011 13
Table 6: Denmark pharmaceuticals market share: % share, by value, 2011 14
Table 7: Denmark pharmaceuticals market value forecast: $ billion, 2011–16 15
Table 8: Denmark size of population (million), 2007–11 24
Table 9: Denmark gdp (constant 2000 prices, $ billion), 2007–11 24
Table 10: Denmark gdp (current prices, $ billion), 2007–11 24
Table 11: Denmark inflation, 2007–11 25
Table 12: Denmark consumer price index (absolute), 2007–11 25
Table 13: Denmark exchange rate, 2007–11 25
Table 14: Norway pharmaceuticals market value: $ billion, 2007–11 27
Table 15: Norway pharmaceuticals market geography segmentation: $ billion, 2011 28
Table 16: Norway pharmaceuticals market share: % share, by value, 2011 29
Table 17: Norway pharmaceuticals market value forecast: $ billion, 2011–16 30
Table 18: Norway size of population (million), 2007–11 39
Table 19: Norway gdp (constant 2000 prices, $ billion), 2007–11 39
Table 20: Norway gdp (current prices, $ billion), 2007–11 39
Table 21: Norway inflation, 2007–11 40
Table 22: Norway consumer price index (absolute), 2007–11 40
Table 23: Norway exchange rate, 2007–11 40
Table 24: Sweden pharmaceuticals market value: $ billion, 2007–11 42
Table 25: Sweden pharmaceuticals market geography segmentation: $ billion, 2011 43
Table 26: Sweden pharmaceuticals market share: % share, by value, 2011 44
Table 27: Sweden pharmaceuticals market value forecast: $ billion, 2011–16 45
Table 28: Sweden size of population (million), 2007–11 54
Table 29: Sweden gdp (constant 2000 prices, $ billion), 2007–11 54
Table 30: Sweden gdp (current prices, $ billion), 2007–11 54
Table 31: Sweden inflation, 2007–11 55
Table 32: Sweden consumer price index (absolute), 2007–11 55
Table 33: Sweden exchange rate, 2007–11 55
Table 34: Pfizer Inc.: key facts 56
Table 35: Pfizer Inc.: key financials ($) 57
Table 36: Pfizer Inc.: key financial ratios 57
Table 37: GlaxoSmithKline Plc: key facts 59
Table 38: GlaxoSmithKline Plc: key financials ($) 60
Table 39: GlaxoSmithKline Plc: key financials (£) 61
Table 40: GlaxoSmithKline Plc: key financial ratios 61
Table 41: Orifarm A/S: key facts 63
Table 42: Pfizer Inc.: key facts 64
Table 43: Pfizer Inc.: key financials ($) 65
Table 44: Pfizer Inc.: key financial ratios 65
Table 45: AstraZeneca PLC: key facts 67
Table 46: AstraZeneca PLC: key financials ($) 68
Table 47: AstraZeneca PLC: key financial ratios 69
Table 48: Johnson & Johnson: key facts 71
Table 49: Johnson & Johnson: key financials ($) 72
Table 50: Johnson & Johnson: key financial ratios 72
Table 51: Novartis AG: key facts 74
Table 52: Novartis AG: key financials ($) 75
Table 53: Novartis AG: key financial ratios 75
LIST OF FIGURES
Figure 1: Scandinavia pharmaceuticals industry, revenue ($bn), 2007-16 8
Figure 2: Scandinavia pharmaceuticals industry, revenue ($bn), 2007-11 9
Figure 3: Scandinavia pharmaceuticals industry forecast, revenue ($bn), 2011-16 10
Figure 4: Denmark pharmaceuticals market value: $ billion, 2007–11 12
Figure 5: Denmark pharmaceuticals market geography segmentation: % share, by value, 2011 13
Figure 6: Denmark pharmaceuticals market share: % share, by value, 2011 14
Figure 7: Denmark pharmaceuticals market value forecast: $ billion, 2011–16 15
Figure 8: Forces driving competition in the pharmaceuticals market in Denmark, 2011 16
Figure 9: Drivers of buyer power in the pharmaceuticals market in Denmark, 2011 17
Figure 10: Drivers of supplier power in the pharmaceuticals market in Denmark, 2011 19
Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Denmark, 2011 20
Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Denmark, 2011 22
Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Denmark, 2011 23
Figure 14: Norway pharmaceuticals market value: $ billion, 2007–11 27
Figure 15: Norway pharmaceuticals market geography segmentation: % share, by value, 2011 28
Figure 16: Norway pharmaceuticals market share: % share, by value, 2011 29
Figure 17: Norway pharmaceuticals market value forecast: $ billion, 2011–16 30
Figure 18: Forces driving competition in the pharmaceuticals market in Norway, 2011 31
Figure 19: Drivers of buyer power in the pharmaceuticals market in Norway, 2011 32
Figure 20: Drivers of supplier power in the pharmaceuticals market in Norway, 2011 34
Figure 21: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Norway, 2011 35
Figure 22: Factors influencing the threat of substitutes in the pharmaceuticals market in Norway, 2011 37
Figure 23: Drivers of degree of rivalry in the pharmaceuticals market in Norway, 2011 38
Figure 24: Sweden pharmaceuticals market value: $ billion, 2007–11 42
Figure 25: Sweden pharmaceuticals market geography segmentation: % share, by value, 2011 43
Figure 26: Sweden pharmaceuticals market share: % share, by value, 2011 44
Figure 27: Sweden pharmaceuticals market value forecast: $ billion, 2011–16 45
Figure 28: Forces driving competition in the pharmaceuticals market in Sweden, 2011 46
Figure 29: Drivers of buyer power in the pharmaceuticals market in Sweden, 2011 47
Figure 30: Drivers of supplier power in the pharmaceuticals market in Sweden, 2011 49
Figure 31: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Sweden, 2011 50
Figure 32: Factors influencing the threat of substitutes in the pharmaceuticals market in Sweden, 2011 52
Figure 33: Drivers of degree of rivalry in the pharmaceuticals market in Sweden, 2011 53
Figure 34: Pfizer Inc.: revenues & profitability 58
Figure 35: Pfizer Inc.: assets & liabilities 58
Figure 36: GlaxoSmithKline Plc: revenues & profitability 61
Figure 37: GlaxoSmithKline Plc: assets & liabilities 62
Figure 38: Pfizer Inc.: revenues & profitability 66
Figure 39: Pfizer Inc.: assets & liabilities 66
Figure 40: AstraZeneca PLC: revenues & profitability 69
Figure 41: AstraZeneca PLC: assets & liabilities 70
Figure 42: Johnson & Johnson: revenues & profitability 72
Figure 43: Johnson & Johnson: assets & liabilities 73
Figure 44: Novartis AG: revenues & profitability 76
Figure 45: Novartis AG: assets & liabilities 76
Introduction 7
What is this report about? 7
Who is the target reader? 7
How to use this report 7
Definitions 7
Scandinavia Pharmaceuticals 8
Industry Outlook 8
Pharmaceuticals in Denmark 11
Market Overview 11
Market Data 12
Market Segmentation 13
Market outlook 15
Five forces analysis 16
Macroeconomic indicators 24
Pharmaceuticals in Norway 26
Market Overview 26
Market Data 27
Market Segmentation 28
Market outlook 30
Five forces analysis 31
Macroeconomic indicators 39
Pharmaceuticals in Sweden 41
Market Overview 41
Market Data 42
Market Segmentation 43
Market outlook 45
Five forces analysis 46
Macroeconomic indicators 54
Company Profiles 56
Leading companies 56
Appendix 77
Methodology 77
LIST OF TABLES
Table 1: Scandinavia pharmaceuticals industry, revenue ($bn), 2007-16 8
Table 2: Scandinavia pharmaceuticals industry, revenue ($bn), 2007-11 9
Table 3: Scandinavia pharmaceuticals industry forecast, revenue ($bn), 2011-16 10
Table 4: Denmark pharmaceuticals market value: $ billion, 2007–11 12
Table 5: Denmark pharmaceuticals market geography segmentation: $ billion, 2011 13
Table 6: Denmark pharmaceuticals market share: % share, by value, 2011 14
Table 7: Denmark pharmaceuticals market value forecast: $ billion, 2011–16 15
Table 8: Denmark size of population (million), 2007–11 24
Table 9: Denmark gdp (constant 2000 prices, $ billion), 2007–11 24
Table 10: Denmark gdp (current prices, $ billion), 2007–11 24
Table 11: Denmark inflation, 2007–11 25
Table 12: Denmark consumer price index (absolute), 2007–11 25
Table 13: Denmark exchange rate, 2007–11 25
Table 14: Norway pharmaceuticals market value: $ billion, 2007–11 27
Table 15: Norway pharmaceuticals market geography segmentation: $ billion, 2011 28
Table 16: Norway pharmaceuticals market share: % share, by value, 2011 29
Table 17: Norway pharmaceuticals market value forecast: $ billion, 2011–16 30
Table 18: Norway size of population (million), 2007–11 39
Table 19: Norway gdp (constant 2000 prices, $ billion), 2007–11 39
Table 20: Norway gdp (current prices, $ billion), 2007–11 39
Table 21: Norway inflation, 2007–11 40
Table 22: Norway consumer price index (absolute), 2007–11 40
Table 23: Norway exchange rate, 2007–11 40
Table 24: Sweden pharmaceuticals market value: $ billion, 2007–11 42
Table 25: Sweden pharmaceuticals market geography segmentation: $ billion, 2011 43
Table 26: Sweden pharmaceuticals market share: % share, by value, 2011 44
Table 27: Sweden pharmaceuticals market value forecast: $ billion, 2011–16 45
Table 28: Sweden size of population (million), 2007–11 54
Table 29: Sweden gdp (constant 2000 prices, $ billion), 2007–11 54
Table 30: Sweden gdp (current prices, $ billion), 2007–11 54
Table 31: Sweden inflation, 2007–11 55
Table 32: Sweden consumer price index (absolute), 2007–11 55
Table 33: Sweden exchange rate, 2007–11 55
Table 34: Pfizer Inc.: key facts 56
Table 35: Pfizer Inc.: key financials ($) 57
Table 36: Pfizer Inc.: key financial ratios 57
Table 37: GlaxoSmithKline Plc: key facts 59
Table 38: GlaxoSmithKline Plc: key financials ($) 60
Table 39: GlaxoSmithKline Plc: key financials (£) 61
Table 40: GlaxoSmithKline Plc: key financial ratios 61
Table 41: Orifarm A/S: key facts 63
Table 42: Pfizer Inc.: key facts 64
Table 43: Pfizer Inc.: key financials ($) 65
Table 44: Pfizer Inc.: key financial ratios 65
Table 45: AstraZeneca PLC: key facts 67
Table 46: AstraZeneca PLC: key financials ($) 68
Table 47: AstraZeneca PLC: key financial ratios 69
Table 48: Johnson & Johnson: key facts 71
Table 49: Johnson & Johnson: key financials ($) 72
Table 50: Johnson & Johnson: key financial ratios 72
Table 51: Novartis AG: key facts 74
Table 52: Novartis AG: key financials ($) 75
Table 53: Novartis AG: key financial ratios 75
LIST OF FIGURES
Figure 1: Scandinavia pharmaceuticals industry, revenue ($bn), 2007-16 8
Figure 2: Scandinavia pharmaceuticals industry, revenue ($bn), 2007-11 9
Figure 3: Scandinavia pharmaceuticals industry forecast, revenue ($bn), 2011-16 10
Figure 4: Denmark pharmaceuticals market value: $ billion, 2007–11 12
Figure 5: Denmark pharmaceuticals market geography segmentation: % share, by value, 2011 13
Figure 6: Denmark pharmaceuticals market share: % share, by value, 2011 14
Figure 7: Denmark pharmaceuticals market value forecast: $ billion, 2011–16 15
Figure 8: Forces driving competition in the pharmaceuticals market in Denmark, 2011 16
Figure 9: Drivers of buyer power in the pharmaceuticals market in Denmark, 2011 17
Figure 10: Drivers of supplier power in the pharmaceuticals market in Denmark, 2011 19
Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Denmark, 2011 20
Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Denmark, 2011 22
Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Denmark, 2011 23
Figure 14: Norway pharmaceuticals market value: $ billion, 2007–11 27
Figure 15: Norway pharmaceuticals market geography segmentation: % share, by value, 2011 28
Figure 16: Norway pharmaceuticals market share: % share, by value, 2011 29
Figure 17: Norway pharmaceuticals market value forecast: $ billion, 2011–16 30
Figure 18: Forces driving competition in the pharmaceuticals market in Norway, 2011 31
Figure 19: Drivers of buyer power in the pharmaceuticals market in Norway, 2011 32
Figure 20: Drivers of supplier power in the pharmaceuticals market in Norway, 2011 34
Figure 21: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Norway, 2011 35
Figure 22: Factors influencing the threat of substitutes in the pharmaceuticals market in Norway, 2011 37
Figure 23: Drivers of degree of rivalry in the pharmaceuticals market in Norway, 2011 38
Figure 24: Sweden pharmaceuticals market value: $ billion, 2007–11 42
Figure 25: Sweden pharmaceuticals market geography segmentation: % share, by value, 2011 43
Figure 26: Sweden pharmaceuticals market share: % share, by value, 2011 44
Figure 27: Sweden pharmaceuticals market value forecast: $ billion, 2011–16 45
Figure 28: Forces driving competition in the pharmaceuticals market in Sweden, 2011 46
Figure 29: Drivers of buyer power in the pharmaceuticals market in Sweden, 2011 47
Figure 30: Drivers of supplier power in the pharmaceuticals market in Sweden, 2011 49
Figure 31: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Sweden, 2011 50
Figure 32: Factors influencing the threat of substitutes in the pharmaceuticals market in Sweden, 2011 52
Figure 33: Drivers of degree of rivalry in the pharmaceuticals market in Sweden, 2011 53
Figure 34: Pfizer Inc.: revenues & profitability 58
Figure 35: Pfizer Inc.: assets & liabilities 58
Figure 36: GlaxoSmithKline Plc: revenues & profitability 61
Figure 37: GlaxoSmithKline Plc: assets & liabilities 62
Figure 38: Pfizer Inc.: revenues & profitability 66
Figure 39: Pfizer Inc.: assets & liabilities 66
Figure 40: AstraZeneca PLC: revenues & profitability 69
Figure 41: AstraZeneca PLC: assets & liabilities 70
Figure 42: Johnson & Johnson: revenues & profitability 72
Figure 43: Johnson & Johnson: assets & liabilities 73
Figure 44: Novartis AG: revenues & profitability 76
Figure 45: Novartis AG: assets & liabilities 76
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.